WUXI BIOLOGICS
WuXi Biologics is a open-access technology platform company offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. Across the global biologics research and development community, we enable our partners to find innovative biological treatments for diseases worldwide.
WUXI BIOLOGICS
Industry:
Health Care Pharmaceutical
Founded:
2014-01-01
Status:
Active
Contact:
+86 (510)-8183-1205
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Altamira Therapeutics
Altamira Therapeutics develops novel pharmaceutical therapies to prevent and treat severe inner ear disorders.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Employees Featured
Shaymaa Taieb Associate Director, upstream Continious Manufacturing @ WuXi Biologics
Associate Director, upstream Continious Manufacturing
2019-08-01
Weichang Zhou Chief Technology Officer & Executive Vice President @ WuXi Biologics
Chief Technology Officer & Executive Vice President
Christine Lu-Wong Chief Financial Officer & Executive Vice President @ WuXi Biologics
Chief Financial Officer & Executive Vice President
Zhisheng Chen Chief Executive Officer @ WuXi Biologics
Chief Executive Officer
2016-01-01
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-03-17 | CMAB BioPharm | CMAB BioPharm acquired by WuXi Biologics | N/A |
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-05-19 | Duality Biologics | WuXi Biologics investment in Series B - Duality Biologics | 90 M USD |
| 2020-09-30 | Invetx | WuXi Biologics investment in Series A - Invetx | 10.25 M USD |
| 2020-02-24 | Invetx | WuXi Biologics investment in Series A - Invetx | 15 M USD |
| 2019-05-21 | Inhibrx | WuXi Biologics investment in Convertible Note - Inhibrx | 40 M USD |
| 2019-04-23 | Duoning Biotech | WuXi Biologics investment in Series A - Duoning Biotech | 100 M CNY |
More informations about "WuXi Biologics"
WuXi Biologics - Wikipedia
WuXi Biologics is a global Contract Research Development and Manufacturing Organization (CRDMO) that provides open-access, integrated technology platforms for biologics drug development. WuXi Biologics' roots date back to 2010, and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices (GMP). WuXi Biologics …See details»
WuXi Biologics withdraws from 2024 BIO convention amid …
May 1, 2024 Amid a U.S. biosecurity crackdown targeting certain Chinese manufacturers and contract research organizations, production specialist WuXi Biologics has quietly exited what …See details»
WuXi Biologics - Crunchbase Investor Profile
WuXi Biologics is a open-access technology platform company offering end-to-end solutions to empower organizations to discover, develop, and …See details»
WuXi Biologics - MVA
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to …See details»
WuXi Biologics Recognized as Industry and Regional ESG Top …
Feb 10, 2025 WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been …See details»
WuXi Biologics Faces Uncertain Future in the U.S. After …
Oct 8, 2024 While WuXi Biologics was at first spared from being named in the BIOSECURE Act when it was introduced to U.S. Congress late last year, a revision of the bill introduced in May added the Chinese-based contract …See details»
WuXi Biologics ESG
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics …See details»
WuXi Biologics - Biocom CRO
WuXi Biologics, a leading contract research, development and manufacturing organization (CRDMO), provides end-to-end capabilities to healthcare organizations worldwide.With …See details»
WuXi STA and WuXi Biologics Jointly Established WuXi …
May 14, 2021 About WuXi Biologics. WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, …See details»
WuXi Biologics divests German drug product plant in …
2 days ago China’s WuXi Biologics is selling its drug product (DP) plant in Leverkusen, Germany for approximately $168 million to Japan’s Terumo Corporation. The deal, subject to customary closing conditions, is expected to …See details»
Wuxi AppTec, WuXi Biologics boost lobbying spending amid rising …
Jul 24, 2024 Among the key players are WuXi Biologics and its parent company, WuXi AppTec, two of China's largest contract research development and manufacturing organization (CDMO) …See details»
WuXi Bio, WuXi XDC upbeat on 2025 after strong 2024 earnings
Mar 25, 2025 Aside from WuXi XDC, the company’s contracting sibling WuXi Biologics also touted solid 2024 performance this week, tallying 9.6% year-over-year sales growth to nearly …See details»
Driving Impact Through Responsibility: WuXi Biologics Releases …
Apr 29, 2025 About WuXi Biologics. WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to …See details»
WXXWY - Wuxi Biologics Latest Stock News & Market Updates
Apr 29, 2025 WuXi Biologics (WXXWY) is a global Contract Research, Development and Manufacturing Organization (CRDMO) offering an integrated and open-access technology …See details»
Leadership - WuXi Biologics
WuXi Biologics has over 12,000 employees, including more than 4200 scientists with advanced degrees and rich work experience in biologics development, manufacturing, quality control, …See details»
WuXi Biologics Ireland: Delivering Measurable Sustainability …
2 days ago WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that …See details»
WuXi Biologics Recognized by CDP for Climate Change Leadership …
Apr 22, 2025 WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been …See details»
Capabilities - WuXi Biologics
Quality. Expertise. Capacity. Speed. These are cornerstones of every service WuXi Biologics provides across the discovery to commercialization spectrum. Our CRDMO service offering …See details»
Driving Impact Through Responsibility: WuXi Biologics Releases …
Hong Kong, China, April 29, 2025 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today …See details»
Services & Solutions – Mammalian – Manufacturing - WuXi Biologics
WuXi Biologics operates multiple state-of-the-art, premier quality cGMP drug substance and drug product production facilities across four countries for a wide variety of biologics (e.g., …See details»